Literature DB >> 19676109

An evaluation of lower-body functional limitations among long-term survivors of 11 different types of cancers.

Mario Schootman1, Rebecca Aft, Donna B Jeffe.   

Abstract

BACKGROUND: The authors examined potential reasons (sociodemographics, psychologic distress, health behavior, chronic health conditions, access to medical care) for increased prevalence of lower-body functional limitations among long-term (> or =5 years) cancer survivors.
METHODS: The authors used National Health Interview Survey data from 2005 through 2007, and defined lower-body functional limitation as reporting difficulty/inability to perform at least 1 of 5 activities (walking approximately one-quarter of a mile; walking up and down 10 steps without rest; standing for 2 hours; stooping, crouching, or kneeling; and lifting 10 lbs). Increased prevalence of lower-body functional limitations was compared between long-term survivors of each of 11 cancer types reported by > or =50 respondents (n = 2143) and persons without cancer history (controls; n = 72,618).
RESULTS: Among cancer survivors, 57.0% had a lower-body functional limitation versus 26.6% of controls. The unadjusted prevalence of lower-body functional limitations varied by cancer type, ranging from 44.9% (lymphoma survivors) to 88.8% (lung cancer survivors). Long-term lung (odds ratio [OR], 7.91), uterine (OR, 2.41), thyroid (OR, 2.27), cervical (OR, 1.76), ovarian (OR, 1.75), and breast (OR, 1.35) cancer survivors had increased odds of reporting a lower-body functional limitation than controls after adjusting for sociodemographic factors (all P < .05). Differences in the prevalence of arthritis and lower-back pain and in access to medical care explained differences in lower-body functional limitation prevalence between controls and long-term breast, cervical, ovarian, and uterine cancer survivors. Long-term bladder, colorectal, lymphoma, melanoma, and prostate cancer survivors were equally likely to report a lower-body functional limitation as controls.
CONCLUSIONS: Treatment of arthritis and lower-back pain and increasing access to medical care might help reduce the risk of lower-body functional limitations and improve quality of life among specific long-term cancer survivors.

Entities:  

Mesh:

Year:  2009        PMID: 19676109      PMCID: PMC2791371          DOI: 10.1002/cncr.24606

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  31 in total

1.  Health-related quality of life and occurrence of intestinal side effects after pelvic radiotherapy--evaluation of long-term effects of diagnosis and treatment.

Authors:  A Bye; C Tropé; J H Loge; M Hjermstad; S Kaasa
Journal:  Acta Oncol       Date:  2000       Impact factor: 4.089

2.  Rheumatoid arthritis masked by docetaxel chemotherapy in a patient with ovarian carcinoma.

Authors:  Marc A Callender; Emmanuel S Antonarakis
Journal:  J Clin Rheumatol       Date:  2008-04       Impact factor: 3.517

3.  Neighborhood environment and loss of physical function in older adults: evidence from the Alameda County Study.

Authors:  Jennifer L Balfour; George A Kaplan
Journal:  Am J Epidemiol       Date:  2002-03-15       Impact factor: 4.897

4.  Preclinical mobility disability predicts incident mobility disability in older women.

Authors:  L P Fried; K Bandeen-Roche; P H Chaves; B A Johnson
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2000-01       Impact factor: 6.053

5.  The persistent impact of breast carcinoma on functional health status: prospective evidence from the Nurses' Health Study.

Authors:  Y L Michael; I Kawachi; L F Berkman; M D Holmes; G A Colditz
Journal:  Cancer       Date:  2000-12-01       Impact factor: 6.860

6.  Health-related quality of life in cervical cancer survivors: a population-based survey.

Authors:  Ida J Korfage; Marie-Louise Essink-Bot; Floortje Mols; Lonneke van de Poll-Franse; Roy Kruitwagen; Marjolein van Ballegooijen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-09-25       Impact factor: 7.038

7.  Fatigue and proinflammatory cytokine activity in breast cancer survivors.

Authors:  Julienne E Bower; Patricia A Ganz; Najib Aziz; John L Fahey
Journal:  Psychosom Med       Date:  2002 Jul-Aug       Impact factor: 4.312

Review 8.  Aromatase inhibitor-associated arthralgia syndrome.

Authors:  Harold J Burstein
Journal:  Breast       Date:  2007-03-21       Impact factor: 4.380

9.  Major depression as a risk factor for chronic disease incidence: longitudinal analyses in a general population cohort.

Authors:  Scott B Patten; Jeanne V A Williams; Dina H Lavorato; Geeta Modgill; Nathalie Jetté; Michael Eliasziw
Journal:  Gen Hosp Psychiatry       Date:  2008-07-23       Impact factor: 3.238

Review 10.  Arthritis burden and impact are greater among U.S. women than men: intervention opportunities.

Authors:  Kristina A Theis; Charles G Helmick; Jennifer M Hootman
Journal:  J Womens Health (Larchmt)       Date:  2007-05       Impact factor: 2.681

View more
  15 in total

1.  The recursive effects of quality of life and functional limitation among older adult cancer patients: evidence from the Survey of Health, Ageing and Retirement in Europe.

Authors:  Y Hamama-Raz; A Shrira; M Ben-Ezra; Y Palgi
Journal:  Eur J Cancer Care (Engl)       Date:  2015-02-09       Impact factor: 2.520

2.  Inpatient oncology rehabilitation in Toronto: a descriptive 18-month retrospective record review.

Authors:  Sara E McEwen; Sarah Elmi; Murray Waldman; Mila Bishev
Journal:  Support Care Cancer       Date:  2011-08-05       Impact factor: 3.603

3.  Patient-reported versus objectively-measured physical function and mortality risk among cancer survivors.

Authors:  Justin C Brown; Michael O Harhay; Meera N Harhay
Journal:  J Geriatr Oncol       Date:  2016-02-18       Impact factor: 3.599

4.  Aging-Related Disease Risks among Young Thyroid Cancer Survivors.

Authors:  Brenna E Blackburn; Patricia A Ganz; Kerry Rowe; John Snyder; Yuan Wan; Vikrant Deshmukh; Michael Newman; Alison Fraser; Ken Smith; Kimberly Herget; Jaewhan Kim; Anne C Kirchhoff; Christina Porucznik; Heidi Hanson; Marcus Monroe; Mia Hashibe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-22       Impact factor: 4.254

5.  Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach.

Authors:  Susan K Lutgendorf; Eileen Shinn; Jeanne Carter; Susan Leighton; Keith Baggerly; Michele Guindani; Bryan Fellman; Marianne Matzo; George M Slavich; Marc T Goodman; William Tew; Jenny Lester; Kathleen M Moore; Beth Y Karlan; Douglas A Levine; Anil K Sood
Journal:  Gynecol Oncol       Date:  2017-05-17       Impact factor: 5.482

6.  Effects of a multicomponent physical activity behavior change intervention on breast cancer survivor health status outcomes in a randomized controlled trial.

Authors:  Laura Q Rogers; Kerry S Courneya; Stephen J Carter; Philip M Anton; Steven Verhulst; Sandra K Vicari; Randall S Robbs; Edward McAuley
Journal:  Breast Cancer Res Treat       Date:  2016-08-18       Impact factor: 4.872

7.  Chronic disease burden among cancer survivors in the California Behavioral Risk Factor Surveillance System, 2009-2010.

Authors:  Heather P Tarleton; Suzanne Ryan-Ibarra; Marta Induni
Journal:  J Cancer Surviv       Date:  2014-04-09       Impact factor: 4.442

8.  National estimates of racial disparities in health status and behavioral risk factors among long-term cancer survivors and non-cancer controls.

Authors:  Mario Schootman; Anjali D Deshpande; Sandi L Pruitt; Rebecca Aft; Donna B Jeffe
Journal:  Cancer Causes Control       Date:  2010-04-17       Impact factor: 2.506

9.  Self-reported major mobility disability and mortality among cancer survivors.

Authors:  Justin C Brown; Michael O Harhay; Meera N Harhay
Journal:  J Geriatr Oncol       Date:  2018-03-14       Impact factor: 3.599

10.  Cancer and treatment-related symptoms are associated with mobility disability in women with ovarian cancer: A cross-sectional study.

Authors:  Grace Campbell; Teresa Hagan; Stephanie Gilbertson-White; Martin Houze; Heidi Donovan
Journal:  Gynecol Oncol       Date:  2016-09-18       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.